Haemonetics Corporation Common Stock (NY:HAE)

119.56 +1.24 (+1.04%)

Delayed Quote Updated: 1:39 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Haemonetics (HAE): Buy, Sell, or Hold Post Q2 Earnings?

October 21, 2026

Haemonetics has been on fire lately. In the past six months alone, the company’s stock price has rocketed 96.3%, reaching $118.21 per share. This was partly ...

Via StockStory

Topics Supply Chain

1 Surging Healthcare Stock Worth Your Attention and 2 We Turn Down

October 16, 2026

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...

Via StockStory

3 Cash-Producing Stocks Walking a Fine Line

October 09, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

Top stock movements in today's session. ↗

October 08, 2026

Via Chartmill

Haemonetics (NYSE:HAE): A Quality Investing Candidate Built on Durable Fundamentals ↗

September 26, 2026

Via Chartmill

Haemonetics (NYSE:HAE) Shines in Quality Investing Screen ↗

August 15, 2026

Via Chartmill

Haemonetics (HAE) Shares Skyrocket, What You Need To Know

October 08, 2026

What Happened? Shares of blood products company Haemonetics (NYSE:HAE) jumped 12.4% in the morning session after CSL Plasma announced intentions to complete ...

Via StockStory

Topics Earnings

Traders are paying attention to the gapping stocks in Thursday's session. ↗

October 08, 2026

Via Chartmill

Thursday's pre-market session: top gainers and losers ↗

October 08, 2026

Via Chartmill

3 Small-Cap Stocks with Questionable Fundamentals

October 01, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

Via StockStory

1 Momentum Stock with Competitive Advantages and 2 We Avoid

September 17, 2026

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...

Via StockStory

Topics Artificial Intelligence

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

September 15, 2026

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

2 Momentum Stocks with Exciting Potential and 1 We Avoid

August 24, 2026

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...

Via StockStory

Winners And Losers Of Q2: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks

August 20, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Haemonetics (NYSE:HAE) and it...

Via StockStory

1 Russell 2000 Stock with Competitive Advantages and 2 We Turn Down

August 20, 2026

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...

Via StockStory

Haemonetics Shares Hit New 52-Week High: What's Happening? ↗

August 18, 2026

Shares of Haemonetics Corp (NYSE: HAE) are trading higher Tuesday afternoon following news of a significant commercial agreement.

Via Benzinga

Tuesday's session: gap up and gap down stocks ↗

August 18, 2026

Via Chartmill

August 17, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

Haemonetics (HAE) Q1 2027 Earnings Call Transcript ↗

August 13, 2026

Plasma disposables surged 25% as Persona PLUS adoption accelerated globally.

Via The Motley Fool

Topics Earnings

5 Insightful Analyst Questions From Haemonetics’s Q2 Earnings Call

August 13, 2026

Haemonetics delivered a Q2 performance that surpassed Wall Street’s revenue and adjusted earnings expectations, supported by consistent execution across its ...

Via StockStory

Topics Earnings

Haemonetics Q1 Earnings Call Highlights ↗

August 08, 2026

Haemonetics (NYSE:HAE) reported a stronger start to fiscal 2027, with first-quarter revenue rising 6% year over year to $339 million and adjusted diluted earnings per share increasing 4% to $1.14. The...

Via MarketBeat

Topics Earnings

HAE Q2 Deep Dive: Plasma and Interventional Growth Drive Outperformance, Margin Outlook Steady

August 07, 2026

Blood products company Haemonetics (NYSE:HAE) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.6% year on year to $339.4 million. Its no...

Via StockStory

Topics World Trade

Haemonetics (NYSE:HAE) Beats Q2 CY2026 Sales Expectations

August 06, 2026

Blood products company Haemonetics (NYSE:HAE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 5.6% year on year to $339....

Via StockStory

What To Expect From Haemonetics’s (HAE) Q2 Earnings

August 04, 2026

Blood products company Haemonetics (NYSE:HAE) will be reporting results this Thursday before market open. Here’s what to look for. Haemonetics beat analysts’...

Via StockStory

1 Cash-Producing Stock with Promising Prospects and 2 That Underwhelm

July 28, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...

Via StockStory

3 Healthcare Stocks with Questionable Fundamentals

July 23, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized stron...

Via StockStory

1 Small-Cap Stock Worth Your Attention and 2 That Underwhelm

July 15, 2026

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...

Via StockStory

3 Reasons HAE is Risky and 1 Stock to Buy Instead

June 30, 2026

Over the last six months, Haemonetics’s shares have sunk to $75.12, producing a disappointing 7.2% loss - a stark contrast to the S&P 500’s 6.1% gain. This m...

Via StockStory

Topics Stocks Supply Chain

3 Profitable Stocks We Find Risky

June 26, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

Haemonetics (HAE) Stock Is Up, What You Need To Know

May 22, 2026

What Happened? Shares of blood products company Haemonetics (NYSE:HAE) jumped 4.1% in the afternoon session after BofA Securities upgraded its rating on the ...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.